NINA LONG: Open Payments
NPI 1205691367 · CULLMAN, AL. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$3,089 in 183 payments from 28 companies in 2025. Trend: 2023 $0 · 2024 $2,563 · 2025 $3,089
Food & beverage: $3,089
| Company | Payments | Amount |
|---|---|---|
| Novartis Pharmaceuticals Corporation | 18 | $312 |
| EMD Serono, Inc. | 24 | $272 |
| CSL Behring | 10 | $244 |
| Mallinckrodt Hospital Products Inc. | 10 | $233 |
| Biogen, Inc. | 11 | $225 |
| Amgen Inc. | 14 | $195 |
| TG Therapeutics, Inc. | 9 | $168 |
| Cycle Pharmaceuticals Inc | 11 | $144 |
| Axsome Therapeutics, Inc. | 10 | $141 |
| Genentech USA, Inc. | 8 | $141 |
Products named: KESIMPTA, Hizentra, ACTHAR, UPLIZNA, BRIUMVI, Symbravo, TYSABRI, Ocrevus.
Industry payments across AL — which companies pay providers there.
